

ASX ANNOUNCEMENT

1 October 2020

Entitlement Offer cleansing notice under section 708AA(2)(f) of the *Corporations Act 2001* (Cth)

Kazia Therapeutics Limited ACN 063 259 754 (**KZA**) announced today that it will undertake a 1 for 3 pro rata accelerated non-renounceable entitlement offer of fully paid ordinary shares in KZA (**New Shares**) to raise approximately \$25.2 million (**Entitlement Offer**).

Bell Potter Securities Limited is acting as lead manager to the Entitlement Offer (the **Lead Manager**).

The offer price for the Entitlement Offer will be \$0.80 per New Share (**Offer Price**).

Under the Entitlement Offer, eligible shareholders will be able to subscribe for 1 New Share for every 3 existing ordinary shares in KZA held at 7.00pm (Sydney time) on 5 October 2020 (**Record Date**) at the Offer Price (**Entitlements**).

The Entitlement Offer includes an institutional component (**Institutional Entitlement Offer**) and a retail component (**Retail Entitlement Offer**).

KZA will offer the New Shares for issue without disclosure to investors under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Corporations Act**) as notionally modified by *ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84* (**ASIC Instrument**).

Further details of the Entitlement Offer are set out in the Investor Presentation that has been lodged with ASX today and the Information Booklet that the Company expects to release to ASX and despatch to eligible shareholders on 8 October 2020.

Details of the securities issued

Class of securities	Ordinary shares
ASX code of the securities	KZA
Date of issue or expected issue of the securities	12 October 2020 for shares issued under the Institutional Entitlement Offer 27 October 2020 for shares issued under the Retail Entitlement Offer
Total number of securities expected to be issued (subject to rounding of fractional entitlements)	31,541,123 New Shares

Information required under section 708AA(7) of the Corporations Act

For the purposes of section 708AA(7) of the Corporations Act, KZA advises as follows:

1. The New Shares will be issued without disclosure under Part 6D.2 of the Corporations Act as notionally modified by the ASIC Instrument.
2. This notice is given under section 708AA(2)(f) of the Corporations Act as notionally modified by the ASIC Instrument.
3. As at the date of this notice, KZA has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to KZA; and
 - (b) section 674 of the Corporations Act.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act, as notionally modified by the ASIC Instrument.
5. The potential effect that the issue of the New Shares will have on the control of KZA, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. However, given:
 - (a) the structure of the Entitlement Offer as a pro rata issue; and
 - (b) the current substantial holdings in KZA (based on the notices given to KZA under section 671B of the Corporations Act prior to the date of this notice),the issue of New Shares pursuant to the Entitlement Offer is not expected to have any material effect or consequence on the control of KZA.

Authorised for release by the Board of Directors.

Signed for and on behalf of KZA.



Kate Hill
Company Secretary